AMG073--ORAL CALCIMIMETIC IN SUBJECT W/ PRIMARY HYPERPARATHYROIDISM

AMG073--原发性甲状旁腺功能亢进症患者口服拟钙剂

• 批准号: 6303684
• 负责人: ROBERT K RUDE
• 金额: $ 3.56万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2000-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6303684
• 关键词: alkaline phosphatase; calcitonin; calcium; clinical research; creatinine; drug /agent; endocrine disorder chemotherapy; human subject; human therapy evaluation; hyperparathyroidism; oral administration; pharmacokinetics

The purpose of this project is to assess the safety & tolerability of daily oral doses of a calcimimetic agent, AMG 073, for 6 weeks in subjects w/primary hyperparathyroidism (HPT) and to assess the clinical effects of AMG 073 by evaluating changes in plasma intact PTH, total serum calcium, calcitonin, and bone specific alkaline phosphatase concentrations and urinary N-telopeptide/ creatinine ratios and characterize the pharmacokinetics of AMP 073 in subjects with HPT.

本项目的目的是在原发性甲状旁腺功能亢进（HPT）受试者中评估每日口服拟钙剂AMG 073 6周的安全性和耐受性，并通过评价血浆完整PTH、总血清钙、降钙素、和骨特异性碱性磷酸酶浓度和尿N-端肽/肌酐比值，并表征AMP 073在HPT受试者中的药代动力学。